Ring 1
Ring 2
Ring 3
Ring 4

Adicet Bio

Adicet Bio is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

View Website


  • Cell Therapy


  • Oncology

Development Status

  • Phase 1

Learn More About Adicet Bio